Methionine deficiency and hepatic injury in a dietary steatohepatitis model

Digestive Diseases and Sciences

Volumn 53, Issue 3, 2008, Pages 767-776

  Oz, Helieh S ^a   Chen, Theresa S ^b   Neuman, Manuela ^c  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

MCD; MCS diets; Methionine

Indexed keywords

AMINOTRANSFERASE; GLUTATHIONE; LIVER ENZYME; METHIONINE; S ADENOSYLMETHIONINE;

AMINO ACID DEFICIENCY; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; ENZYME ACTIVITY; ENZYME ANALYSIS; FATTY LIVER; FEEDING; GENETIC REGULATION; HEMATOCRIT; HEPATITIS; HISTOPATHOLOGY; LIVER INJURY; MALE; METHIONINE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; CHOLINE DEFICIENCY; FATTY LIVER; GENE EXPRESSION; HEPATITIS, ANIMAL; LIVER; MALE; METHIONINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 39849106893     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9900-7     Document Type: Article

References (49)

1. Lee RG, Keeffe EB (1999) Non-alcoholic fatty liver: causes and complications. In: J Bircher, Benhamou JP, McIntyre M et al (eds) Oxford, textbook of clinical hepatology, 2nd edn. Oxford University Press, Oxford, UK, pp 1251-1257
2. Kumar KS, Malet PF (2000) Nonalcoholic steatohepatitis. Mayo Clin Proc 75:733-739
3. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231
4. Fong DG, Nehra V, Lindor KD, Buchman AL (2000) Metabolic and nutritional considerations in non-alcoholic fatty liver. Hepatology 32:3-10
5. Begriche K (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6:1-28
6. Farrell GC (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43:S99-S112
7. Matteoni CA, Younossi Z, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419
8. Powell E, Cooksley WG, Hanson R et al (1990) The natural history of nonalcoholic steatohepatitis: a followup study of forty-two patients for up to 21 years. Hepatology 11:74-80
9. Maheshwari A (2006) Cryptogenic cirrhosis and NAFLD: are they related? Am J Gastroenterol 101:664-668
10. Pessayre D, Fromenty B (2005) NASH: a mitochondrial disease. J Hepatology 42:928-940
11. Caldwell S, Chang Y, Nakamoto R, Krugner-Higby L (2004) Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 8:595-617
12. Browning JD, Horton J (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest, 114:147-152
13. Pessayre D, Feldman G, Haouzi D, Fau A, Moreau A, Neuman MG (1999) Hepatocyte apoptosis triggered by natural substances (cytokines, other endogenous molecules and foreign toxins). In: Cameron RG, Fauer G (eds) Handbook of experimental pharmacology: apoptosis modulation by drugs. vol 142, Chapter 3. Springer Verlag Publishers, Heidelberg, 69-109
14. Weikert M, Pfeiffer A (2006) Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabeteologia 49:1732-1741
15. Reddy J, Sambasiva Rao M (2006) Lipid metabolism and liver inflammation. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290:G852-G858
16. Neuman MG, Valentino K (2003) Caspases, S-Adenosyl methionine, and anti-tumor necrosis factor alpha signaling for protection in ethanol induced apoptosis in normal human hepatocyte. J Hepatol 38(suppl 2, abs. 686):197
17. Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37:1202-1219
18. Wang R, Koretz R, Yee H (2003) Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 115:554-559
19. Enriquez A, Leclercq I, Farrell GC, Robertson G (1999) Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun 255:300-306
20. Weltman MD, Farrell GC, Hall P, lngelman-Sundberg M, Liddle C (1998) Hepatic cytochrome P4502E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27:128-133
21. Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, Thummel KE (2003) CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 38:428-435
22. Raucy JL, Lasker JM, Kramer JC, Salazar DE, Lieber CS, Corcoran GB (1991) Induction of P45OIIE1 in the obese rat. Mol Pharmacol 39:275-280
23. Irizar A, Barnett CR, Flatt PR, Ioannides C (1995) Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rats. Eur J Pharmacol 293:385-393
24. Weltman MD, Farrell GC, Liddle C (1996) Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111:1645-1653
25. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM (2004) Model of nonalcoholic steatohepatitis. Am J Clin Nutr 79:502-509
26. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM (2004) Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 315:699-703
27. Farrell GC (2005) Animal models of steatohepatitis. In: Farrell GC, George J, Hall P, McCullough AJ (eds) Fatty liver disease; NASH and related disorders. Blackwell Publishing, Malden, MA, USA, pp 91
28. Seki S, Kitada T, Sakaguchi H, Nakatani K, Wakasa K (2002) In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol 37:56-62
29. Garcia-Monzon C, Martin-Perez E, Lo Iacono O, Fernandez-Bermejo M, Majano PL et al (2000) Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33:716-724
30. Rashid A, Wu T-C, Huang CC, Chen CH, Lin HZ et al (1999) Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 29:1131-1138
31. Feldstein AE, Canby A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ (2003) Hepatocyte apoptosis and FAS expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125:437-443
32. Feldman G, Haouzi D, Moreau A, Durang-Schneider A-M, Bringuier A, Berson A, Mansouri A, Fau D, Pessayre D (2000) Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in FAS-mediated hepatic apoptosis in mice. Hepatology 31:674-683
33. Chen TS, Richie JP, Nagasawa HT, Lang CA (2000) Glutathione monoethyl ester protects against glutathione deficiencies due to aging and acetaminophen in mice. Mech Ageing Dev 120:127-139
34. Feher J, Lengyel G (2003) A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J Int Med Res 31:537-551
35. Chawla RK, Watson WH, Eastin CE, Lee EY, Schmidt J, McClain CJ (1998) S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury. Am J Physiol 275:G125-G129
36. Zhu x, Song J, Mar M, Edwards LJ, Zeisel SH (2003) Phosphatidylethanolamine N-methyltrasferase (PEMT) knock mice have hepatic steatosis and abnormal hepatic choline metabolite concentrations despite ingesting a recommended dietary intake of choline. Biochemistry J370:987-993
37. Baker DH (1986) Utilization of isomers and analogs of amino acids and other sulfur- containing compounds. Prog Food Nutr Sci 10:133-178
38. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G (2003) Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Hepatology 39:756-764
39. Weissbach H, Etienne F, Hoshi T, Heinemann SH, Lowther WT, Matthews B, St John G, Nathan C, Brot N (2002) Arch Biochem Biophys 397:172-178
40. Yermolaieva O, Xu R, Schinstock C, Brot N, Weissbach H, Heinemann SH, Hoshi T (2004) Methionine sulfoxide reductase A protects neuronal cells against brief hypoxia/reoxygenation. Proc Natl Acad Sci USA 101:1159-1164
41. Matsui H, Ikeda K, Nakajima Y, Horikawa S, Imanishi Y, Kawada N (2004) Sulfur-containing amino acids attenuate the development of liver fibrosis in rats through down-regulation of stellate cell activation. J Hepatol 40:917-925
42. Oz HS, McClain CJ, Nagasaw HT, Ray MB, de Villiers WSJ, Chen TS (2004) Diverse antioxidants protect against acetaminophen hepatotoxicity. J Biochem Mol Toxicol 18:361-368
43. Oz HS, Chen T, McClain C, de Villiers W (2005) Antioxidants a novel therapy in a murine model of colitis. J Nutr Biochem 16(5):297-304
44. Oz HS, Chen T, Nagasawa H (2007) Comparative efficacies of two cysteine prodrugs and a glutathione delivery agent in a colitis model. Transl Res 150:122-129
45. Oz HS, Hee-Jeong IM, Chen TS, de Villiers WJS, McClain CJ (2006) Glutathione enhancing agents protect against steatohepatitis in a model. J Biochem Mol Toxicol 20:39-47
46. Lu SC (2000) S-Adenosylmethionine. Int J Biochem Cell Biol 32:391-395
47. McClain CJ, Prakash S Mokshagundam L, Barve S, Song Z, Hill D, Chen T (2004) Deaciuc I mechanisms of non-alcoholic steatohepatitis. Alcohol 34:67-79
48. Donthamsetty S, Bhave VS, Mitra MS, Latendresse JR, Mehendale HM (2007) Nonalcoholic fatty liver sensitizes rats to carbon tetrachloride hepatotoxicity. Hepatology 45(2):391-411
49. Miele L, Forgione A, Hernandez AP, Gabrieli ML, Vero V, Di Rocco P, Greco AV, Gasbarrini G, Gasbarrini A, Grieco A (2005) The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis. Eur Rev Med Pharmacol Sci 9:273-278